Normosang (Human Hemin)

Human Hemin supplies external heme that feeds back to inhibit hepatic δ‑aminolevulinic acid synthase 1 (ALAS1), the first enzyme in the heme biosynthetic pathway. By down‑regulating ALAS1, the drug reduces the synthesis of aminolevulinic acid and porphobilinogen, preventing the buildup of neurotoxic intermediates that trigger acute porphyria crises.

The dosing regimen for Normosang is individualized and must be determined by a qualified prescriber based on the severity of the porphyria attack, patient weight, and clinical response. Physicians calculate the appropriate amount and infusion rate, and the medication is administered intravenously under medical supervision.

Safety data for Normosang in pregnancy and lactation are limited, and the product’s pregnancy category is not established. Use during pregnancy or while breastfeeding should only occur if the potential benefit justifies the potential risk to the fetus or infant, and it must be decided by the treating physician.

To request Normosang, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and necessary import documentation.

Normosang (human hemin) is a purified, lyophilized heme preparation similar in action to other heme products such as heme arginate. All provide exogenous heme to suppress ALAS1, but formulation differences may affect stability, infusion volume, and storage requirements. Clinical choice often depends on regional availability, regulatory approval, and physician preference.

Normosang must be stored at 2‑8 °C in a refrigerator, protected from light, and should not be frozen or shaken. The vial should remain in its original packaging until use, and any reconstituted solution should be administered promptly according to the manufacturer’s instructions to maintain potency.

Normosang is supplied as an injectable solution for intravenous infusion. The medication is reconstituted according to the label directions, then infused slowly—typically over 30 minutes to an hour—under clinical supervision. Vital signs are monitored throughout the infusion to detect any adverse reactions.

The most serious risks include hypotension, anaphylactic reactions, and hemolysis, each of which can be life‑threatening and require immediate medical intervention. Patients should be observed closely during and after infusion, and any signs of severe allergic response, sudden blood pressure drop, or rapid hemoglobin decline must be reported promptly.

Normosang is contraindicated in patients with known hypersensitivity to human hemin or any excipients in the formulation. It should also be avoided in individuals with severe iron overload conditions or uncontrolled cardiovascular disease where rapid heme infusion could exacerbate instability. Clinical judgment determines suitability for each patient.